Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT03077893 · ClinicalTrials.gov registry record · NA

Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy

A NA study of Diabetic Peripheral Neuropathy, sponsored by Regenesis Biomedical.

Completed
Registry status
NA
Development phase
44
Enrollment target
1
Study location

NCT03077893 is a NA study of Diabetic Peripheral Neuropathy that has completed, run by Regenesis Biomedical. The registered enrollment target is 44 participants, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT03077893, a NA study of Diabetic Peripheral Neuropathy, has completed, sponsored by Regenesis Biomedical.

COMPLETED
Registry status
NA
Development phase
44 participants
Enrollment target
1
Study location

Study Summary

A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.

Interventions

  • DEVICE Active Provant Therapy System
  • DEVICE Inactive (sham) Provant Therapy System

Study Locations (1)

Arizona

  • Associated Foot & Ankle Specialists, LLC - Phoenix

Trial Details

FieldValue
Enrollment Target 44 participants
Start Date 2017-03-09
Est. Completion 2017-12-26
Phase NA

Sponsor

Regenesis Biomedical

10 total trials

What the Registry Record Tells You About NCT03077893

The ClinicalTrials.gov registry entry for NCT03077893 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 44 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 126-participant average among 17 other Diabetic Peripheral Neuropathy trials with a reported enrollment target (65% lower). The listed sponsor is Regenesis Biomedical, which has 10 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Diabetic Peripheral Neuropathy appearing as the primary indexed condition, and to 2 interventions - of which Active Provant Therapy System is the first listed.

NCT03077893 reports 1 study location spanning 1 distinct geographic area - top geographies include Arizona.

Frequently Asked Questions

What is clinical trial NCT03077893 about?

NCT03077893 is a clinical study titled "Study of PEMF to Evaluate VPT and Thermal Sensory in Subjects With Diabetic Peripheral Neuropathy". A study to demonstrate the effectiveness of PEMF treatment compared to sham treatment in changing Vibration Perception Threshold (VPT) and Thermal Sensory (QST) in patients with diabetic peripheral neuropathy (DPN) when treatment is administered twice daily through 120-day period.

What is the current status of trial NCT03077893?

This trial is currently completed. It is a NA study. The enrollment target is 44 participants. The study started on 2017-03-09. Estimated completion is 2017-12-26.

What conditions does trial NCT03077893 study?

This clinical trial studies the following conditions: Diabetic Peripheral Neuropathy.

What interventions are being tested in trial NCT03077893?

The interventions under investigation include: Active Provant Therapy System (DEVICE), Inactive (sham) Provant Therapy System (DEVICE).

Who is sponsoring clinical trial NCT03077893?

This trial is sponsored by Regenesis Biomedical, which has 10 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT03077893 being conducted?

This trial has 1 study location across Arizona. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Diabetic Peripheral Neuropathy

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.